Alongside the Make America Healthy Again movement, nicotine is being repackaged as a wellness and performance product. Influencers in social media, podcasts, wellness communities and tech startups describe it as a misunderstood natural compound that might sharpen focus or protect against cognitive decline. The trend includes noncombustible pouches and combinations with caffeine or nootropics. Pulmonologist and nicotine-dependence researcher Hasmeena Kathuria says those promises go well beyond what human studies have established.
Nicotine occurs in tobacco and in trace amounts in tomatoes, potatoes and eggplants. Natural origin does not make it safe: it is the main driver of dependence on cigarettes, e-cigarettes and most commercial tobacco products. Burning tobacco produces thousands of toxic substances, including carcinogens, carbon monoxide and fine particles; repeated exposure can cause cancer, chronic obstructive pulmonary disease and cardiovascular illness. Nicotine itself activates the sympathetic system, raises heart rate and blood pressure, disrupts sleep and can strain the heart. Prenatal exposure has been associated with adverse fetal development, while adolescent exposure can alter neural systems involved in attention, learning and reward.
Nicotine acts on receptors that normally respond to acetylcholine, a neurotransmitter involved in attention, memory and learning, and can temporarily increase alertness. It also affects dopamine reward pathways. But its effects last longer than normal signaling and alter brain activity. With repeated exposure, receptors become less responsive and the brain increases their number, contributing to dependence.
Evidence on cognition is mixed. Some studies suggest temporary improvements in attention, alertness, reaction time and working memory; possible benefits have been reported for mild cognitive impairment. Nicotine does not appear to improve cognition in healthy people and may worsen performance among those who already score highly. Many studies include dependent regular users: after stopping, they can have trouble concentrating, feel irritable, anxious or restless, and nicotine may relieve withdrawal. Apparent improvement may therefore reverse withdrawal rather than enhance ability. Evidence for gains in academic performance, intelligence, creativity, executive function or workplace productivity is limited.
Nicotine may briefly create pleasure or stress relief, but longer-term use can disrupt the body’s stress response. People who quit smoking tend over time to experience less anxiety, depression and stress, with better mood and quality of life. Current evidence does not support nicotine as a treatment for stress, mood disorders, anxiety or depression.
Laboratory and animal findings do not prove claims that nicotine prevents dementia, Alzheimer’s or Parkinson’s disease, slows aging or extends life. Human studies have not demonstrated dementia prevention, slower Alzheimer’s progression, long-term cognitive preservation or better Parkinson’s outcomes. FDA-approved patches, gum and lozenges have a different purpose: when used as directed, they help people quit smoking by reducing cravings and withdrawal. That evidence-based treatment should not be confused with wellness use; nicotine outside a proven effort to stop or reduce tobacco use carries a risk of dependence.